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A B S T R A C T
Despite the widespread availability of highly effective methods of contraception, unintended pregnancy is common.
Unplanned pregnancies have been linked to a range of health, social and economic consequences. Emergency contracep-
tion reduces risk of pregnancy after unprotected intercourse, and represents an opportunity to decrease number of un-
planned pregnancies and abortions. Emergency contraception pills (ECP) prevent pregnancy by delaying or inhibiting
ovulation, without interfering with post fertilization events. If pregnancy has already occurred, ECPs will not be effective,
therefore ECPs are not abortificants. Ulipristal acetate (17a-acetoxy-11b-(4N-N,N-dymethilaminophenyl)-19-norpregna-
-4,9-diene-3,20-dione) is the first drug that was specifically developed and licensed for use as an emergency contracep-
tive. It is an orally active, synthetic, selective progesterone modulator that acts by binding with high affinity to the hu-
man progesterone receptor where it has both antagonist and partial agonist effects. It is a new molecular entity and the
first compound in a new pharmacological class defined by the pristal stem. Up on the superior clinical efficacy evidence,
UPA has been quickly recognized as the most effective emergency contraceptive pill, and recently recommended as the
first prescription choice for all women regardless of the age and timing after intercourse. This article provides literature
review of UPA and its role in emergency contraception.
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Introduction
Despite the widespread availability of highly effective
methods of contraception, unintended pregnancy is com-
mon. In both US and EU it is estimated that about half of
all pregnancies are unplanned1,2. Situation in Croatia is
estimated to be similarly unsatisfactory3. More than half
of unwanted pregnancies – an estimated 45.5. million
worldwide – are resolved by induced abortion each year4.
Unplanned pregnancies have been linked to a range of
health, social and economic consequences1.
Emergency contraception (EC) is defined as the use of
any drug or device used after an unprotected sexual in-
tercourse or contraceptive method failure to prevent an
unwanted pregnancy5. It is an occasional contraception
method and should not replace regular contraception.
EC significantly reduces the risk of unintended preg-
nancy after the sexual intercourse6–8. It has been esti-
mated that millions of unintended pregnancies could be
avoided if effective EC were widely accessible9. While in-
terventions to make EC available have clearly failed in
reducing abortion rates10, it has been well recognized
that EC is underused worldwide. In order to benefit from
lessons learned and to secure positive population impacts
from introducing dedicated ECPs in Croatia, EC meth-
ods and policies have been recently evaluated and four
actionable points were recognized11.
Methods used postcoitally included estrogen only reg-
imen, combination of estrogen and levonorgestrel (LNG),
LNG only, mifepristone and insertion of a copper intra-
uterine device (IUD)6. Recently, a new class of progester-
one receptor modulator ulipristal acetate has been in-
troduced6. Up on the superior clinical efficacy evidence,
UPA has been quickly recognized as the most effective
ECP6,7 and recently recommended as the first choice
ECP12 for all women regardless of the age and timing af-
ter intercourse. UPA is considered to be a pluripotent
molecule, already confirmed to be effective in preopera-
tive treatment of uterine fibroids13,14 and intensively in-
vestigated in various different indications15.
Objective of this paper is to provide overview on UPA
and its role in EC.
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Emergency Contraception
Following unprotected sexual intercourse, pregnancy
is likely to result only during the fertile period that ex-
tends from 5 days before ovulation to the day of ovu-
lation16. Once released, oocyte deteriorates rapidly to a
point where fertilization is unlikely. During this fertile
period probability of conception varies. In estimating the
need for emergency contraception after the unprotected
intercourse, it is important to consider variability of the
ovulation, and major discrepancy observed between wo-
men’s self-report of stage of a menstrual cycle and the
dating calculation based on endocrine data17. As it is dif-
ficult to accurately predict the exact stage of the men-
strual cycle at which unprotected intercourse occured,
emergency contraception is generally indicated at any
time of the cycle6–8.
Yuzpe method was introduced in late 1970s, and con-
sisted of 200 mcg ethinyl estradiol and 1000 mcg le-
vonorgestrel divided in two doses, and given within 72 h
after the intercourse18. It has remained the standard hor-
monal EC method until the introduction of LNG only
and mifepistrone regimens19,20. LNG only regimen is
more effective and causes fewer side effects compared to
the Yuzpe regimen19. It is to be given in a single 1.500
mcg dose within 72 hours after the intercourse. Its key
limitation is decrease in efficacy over the time after the
intercourse, as well as inability to prevent ovulation once
the LH surge has started19–23. Mifepistrone is effective
and well tolerated in EC, but for social and political rea-
sons it is available for EC only in Russia and China16,24.
UPA is the first drug that was specifically developed and
licensed for use as an emergency contraceptive. It is to be
given in a single 30 mg dose, within 120 h after the inter-
course.
A major barrier to the widespread acceptability and
use of EC is concern regarding mechanisms of action of
EC methods. The best available evidence indicates that
emergency contraception pills (ECP) prevent pregnancy
by delaying or inhibiting ovulation6–8,16,23 therefore
ECPS do not seem to interfere with postfertilization
events. Endometrial effects of ECP do not contribute to
their efficacy in EC. If pregnancy has already occurred,
ECPs will not be effective, therefore ECPs are not aborti-
ficants6–8,12. When IUD is used as a regular or emergency
method of contraception, it acts primarily to prevent fer-
tilization. EC insertion of a copper IUD is significantly
more effective than use of ECPs, reducing the risk of
pregnancy by more than 99.9%8,25. Such a high level of ef-
fectiveness implies that emergency insertion of a copper
IUDmight prevent some pregnancies after fertilization6.
The EC should be taken as early as possible but no
later than 120 hours for IUD and UPA, and no later than
72 hours for LNG. Inserting IUD for emergency contra-
ception has the advantage of providing further contra-
ception, while all ECP users need to use additional bar-
rier methods till end of the cycle during which they took
ECP6.
UPA – Structure
The development of molecules with specific steroid
antagonist properties holds great promise for a variety of
therapeutic applications. Ulipristal acetate (17a-acetoxy-
-11b-(4N-N,N-dymethilaminophenyl)-19-norpregna-4,9-
diene-3,20-dione) was first synthesized by Research Tri-
angle Institute under a contract with the National Insti-
tute of Child Health and Human Development (NICHD)
for the development of new compounds that exhibit se-
lective inhibition of the progesterone receptor with mini-
mal effect on other steroid receptors. It is therefore a
new molecular entity and the first compound in a new
pharmacological class defined by the pristal stem. Its
hormonal and antihormonal activity, selectivity and po-
tency of its proximal metabolites were thoroughly evalu-
ated26,27.
UPA – Pharmacodynamics
UPA is an orally active, synthetic, selective progester-
one modulator that acts by binding with high affinity to
the human progesterone receptor28,29, where it has both
antagonist and partial agonist effects21. The drug has
minimal affinity for the androgen receptor and no affin-
ity for the human estrogen or mineralocortocoid recep-
tors29. Although UPA has demonstrated some affinity for
gluccocorticoid receptor in animals, no antiglucocorticoid
effects have been observed in humans. Moreover, its
glucocorticoid receptor antagonist activity is much re-
duced compared to that of mifepistrone27 indicating that
ulipristal acetate belongs to a new class of progesterone
receptor modulators with dissociated glucocorticoid ac-
tivity.
The key UPA mechanism of action in emergency con-
traception is to inhibit or to delay ovulation, although it
is not fully clear by which mechanism this occurs23,26–29.
A series of clinical pharmacodnynamics studies found
that when administered at a point in the menstrual cycle
prior to the onset of the LH surge, or before the peak in
LH level had been reached, UPA significantly delays the
LH peak by at least five days. When administered prior
to the LH peak, UPA significantly delayed follicular
rupture31. In a placebo controlled study in women with
normal menstrual cycles, single doses of UPA 10, 50, 100
mg administered at the mid follicular stage with the folli-
cle diameter of 14–16 mm significantly suppressed lead
follicle growth, which lead to a dose dependent delay in
folliculogenesis and plasma estradiol levels suppres-
sion31. Double blind crossover randomized placebo con-
trolled study demonstrated that a single UPA dose of 30
mg given immediately prior ovulation significantly de-
layed follicular rupture even in women in whom LH
surge has already commenced23. This indicates that UPA
is effective during a longer period compared to LNG,
which needs to be administered before the onset of LH
surge in order to effectively prevent pregnancy22. How-
ever it is important to recognize that if UPA is adminis-
tered after the LH peak being reached, follicular rupture
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is not delayed23. Animal studies indicate that UPA may
have a direct inhibitory effect on follicular rupture30.
Endometrial effects of UPA were shown to be dose de-
pendent. Following a single UPA dose of 10, 50 and 100
mg given in the early luteal phase and within 2 days of
LH surge, endometrial thickness was reduced in a dose
dependent manner with statistic difference, for all doses
combined and vs. placebo32. The decrease between 10 and
50 mg appeared to be minimal. In addition to this, alter-
ations in progesterone dependent markers of implanta-
tion also were observed in endometrial glandular epi-
thelium32.
UPA had a dose dependent effect on menses when ad-
ministered in mid luteal phase. Higher doses (100–200
mg) were associated with earlier menses (33 ADIS 20)
Clinical trials have showed that a cycle length was in-
creases by a mean of 2.5 days. There was no indicator of
cycle lenght being influenced by the time of the men-
strual cycle in which UPA was given (34 ADIS 21).
UPA – Pharmacokinetics
In a study of 20 women under fasting conditions fol-
lowing the administration of a single 30 mg oral dose,
UPA was demonstrated to be rapidly absorbed. It reached
mean peak plasma concentrations (Cmax) of the drug
and its major active metabolite mono-demethylated uli-
prisal acetate of 176 ng/mL and 69 ng/mL respectively at
0.9 and 1.0 hours28,29. Corresponding values for the area
under the plasma concentration-time curve from time
zero to infinity AUC were 556 and 246 ng h/mL.
A high fat meal reduces mean Cmax by –45%, and de-
lays tmax from a median of 0.75 hours to 3 hours, and
mean AUC is increased by 24% compared with the ad-
ministration in the fasting state28,29. Similar was ob-
served with the main metabolite. In despite of this find-
ing, phase III trials have not demonstrated any effects of
concomitant food intake and UPA efficacy35.
UPA is highly bound to plasma proteins (>94%) albu-
min, alpha-1-acid-glycoprotein and high density lipopro-
tein28,29. Following ingestion, UPA is intensively metabo-
lized in the liver to mono-demethylated metabolites of
which only the mono-demethylated metabolite is phar-
macologically active. In vitro studies show that metabo-
lism is predominantly mediated by cytochrome P450
(CYP)3A4 enzymes, and to a lesser extent by CYP1A2
and CYP2D628,29.
Excretion of UPA is primarily via the feces. After a
single dose of 30 mg micronized UPA, 32 hours is the es-
timated terminal elimination plasma half-life for UPA,
and 27 for mono-demethylated-ulipristal acetate28,29.
No differences have been observed between women of
different ethnic groups in clinical studies25,26. Pharma-
cokinetic studies in women with renal impairment or in
women aged <16 years have not been performed. Re-
peated UPA doses in animal studies resulted in some em-
bryo-fetal loss, but at doses low enough to maintain ges-
tation, no indication of any teratogenic potential has
been detected28,29. As for any new molecular entity, the
sum of information on the impact of exposure to UPA in
early pregnancy remains limited, however currently rais-
ing no concern. An online registry has been established
in order to facilitate the collection of information on
pregnancies that were exposed to UPA in the early stages
of pregnancy.
Drug interaction studies have not been performed
with UPA. Having in mind major CYP3A4 metabolism
pathway, interactions are possible when co-administered
with agents that induce or inhibit CYP3A428,29. There-
fore, co-administration of CYP3A4 inducers (rifampicin,
phenitoin, phenobarbital, long tem use of ritonavir, ECP
containing levonorgestrel) or agents that increase gastric
pH is not recommended as plasma concentrations of UPA
may be decreased leading to a loss of efficacy.
Having in mind UPA’s affinity for progesterone recep-
tor, it could interfere with progesterone actions. Although
the use of UPA is not contraindicated to the continued
use of regular hormonal contraception, it is possible that
the contraceptive action of combined hormonal contra-
ceptives (CHC) and progesterone only contraceptives
(POC) may be reduced29.
UPA – Efficacy
The effectiveness of a preventive therapy is best mea-
sured by comparing probability that the condition will
occur if the therapy is used to the probability that it will
occur without treatment. For majority of preventive the-
rapies effectiveness is determined by randomized clinical
trials comparing treatment to placebo. In the case of
emergency contraception placebo controlled trials are
considered to be non ethical. Inital EC efficacy was dem-
onstrated in noncomparative observational trials. There-
fore, the chance that pregnancy would occur in the ab-
sence of EC is estimated indirectly using published data
on probability of pregnancy on the each day of the men-
strual cycle38,39. The estimate is compared with the ac-
tual number of pregnancies observed after treatment in
observational treatment trials. EC effectiveness calcula-
tion obviously involves many assumptions that are hard
to validate.
The efficacy of UPA has been evaluated during phase
II and III clinical research: one phase II trial34 and two
phase III38,39 multicentre trials in women requesting
emergency contraception following unprotected sexual
intercourse. Two trials were randomized, single35 or
double34 blind non-inferiority trials that compared preg-
nancy rates between UPA and LNG. The third open label
study39 compared pregnancy rates between UPA and
those estimated in the absence of EC. Two randomized
trials compared the efficacy of UPA and LNG, one up to
72 hours after sexual intercourse34, and the other up to
120 hours after the intercourse38. When these two stud-
ies of a similar design were combined in a meta-analysis,
UPA was found to have 42% lower pregnancy rate than
LNG within 72 hours after the intercourse: in the LNG
treatment group (N=1625) there were 35 pregnancies,
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while in UPA tretment group (N= 1617) there were 22
pregnancies38. Even more important, within 24 hours af-
ter the intercourse, during the day of the best LNG effi-
cacy, UPA was found to have 65% lower pregnancy rate
than LNG: in LNG treatment group (N=600) there were
15 pregnancies, while in UPA group (N=584) there were
5 pregnancies38. In the open label trial, the pregnancy
rate in patients receiving UPA within 48–120 hours from
unprotected sexual intercourse was significantly lower
than that of expected pregnancy rate in the absence of
emergency contraception39. This study delivered another
important learning, that unlike LNG, UPA has demon-
strates sustained efficacy when administered at any time
between 48–120 hours from unprotected intercourse39.
Rational behind significantly lower pregnancy rates
on UPA when compared to LNG seems to be higher UPA
efficacy in postponing imminent ovulation as LNG is no
more effective than placebo in preventing ovulation after
the onset of the LH surge, and after the follicular diame-
ter has reached 15–17 mm. On the contrary, UPA can ef-
fectively delay ovulation even after the onset of the LH
surge (till it reaches its peak concetration), and follicular
diametar reached 18–20 mm. Additional efficacy related
advantage of UPA is sustained efficacy through 120 hours
from unprotected sexual intercourse.
UPA – Tolerability and Safety
In all trials UPA was generally well tolerated, with
majority of side effects being mild to moderate in severity
and resolving spontaneously in 89–94%. Tolerability of
UPA seems to be comparable to LNG34,38,39.
The most frequently reported UPA treatment related
adverse effects were headache, nausea, dymenorrhea and
abdominal pain, a profile similar to that reported in LNG
comparative groups.
In an open lable phase II study the most frequently
reported treatment related adverse effects (AE) of UPA
were headache (9.3%), nausea (9.2%) and abdominal
pain (6.8%)39. Other AE reported in this study were dys-
menorrhoea (4.15%), dizziness (3.5%) and fatigue (3.4%).
In another phase III study UPA was demonstrated to
be as well tolerated as LNG35. The most common adverse
events in UPA and LNG treatment groups were head-
ache (19% vs. 18.5%) nausea (13% vs. 11.5%), dysmenor-
rhoea (13% vs. 14.5%), fatigue (5.5.% vs. 4%) and abdom-
inal pain (5% vs. 6.5%)38.
UPA was generally associated with delayed onset of
menses31,35,36. Mean menstrual cycle length increased by
2.138, 2.631 and 2.839 days in UPA groups, while the onset
of menses was a mean of 1.238 and 2.134 days earlier in
LNG groups.
UPA has not affected the duration of bleeding38.
Intermenstrual bleedings with UPA in most cases
were described as spotting and were reported by 8.7% of
women compared of 3.3% before enrolment39.
There were no changes of clinical significance in com-
plete blood count, hepatic and renal function, lipids and
random glucose analysis in 100 women monitored before
and after UPA treatment36.
There are no medical contraindications to the use of
combined or progestin only ECPs with the exception of
pregnancy6–8,12. UPA is a novel chemical entity and is
contraindicated in existing or suspected pregnancy29. As
for any new molecular entity, the sum of information on
the impact of exposure to UPA in early pregnancy re-
mains limited and currently raising no concern6–8,12,29.
Although no teratogenic potential was observed, animal
data are insufficient with regard to reproduction toxi-
city29. Therefore, a pregnancy registry has been estab-
lished in order to facilitate the collection of information
on pregnancies in EU that were exposed to UPA in early
stages of pregnancy, allowing further investigation29. The
key reason ECP should not be used in pregnancy is not
because they are harmful but because they are ineffec-
tive6.
UPA is lipophilic compound and therefore excreted in
the human milk. Risk to the breast-fed child cannot be
excluded. After the intake of UPA, brestfeed should be
discontinued for a week. During this time it is recom-
mended to express and discard the milk in order to stim-
ulate lactation29.
A rapid return of fertility is likely following UPA
treatment, therefore continuing or initiating regular con-
traception is recommended as soon as possible29.
Conclusion
UPA is the first of a new class selective progesterone
receptor modulators that acts by binding with high affin-
ity to the human progesterone receptor where it has both
antagonist and partial agonist effects. It is the first entity
specifically developed for EC, but it is also intensively in-
vestigated in other indications. UPA provides effective,
sustained and well tolerated emergency contraception
when taken within 120 hours after unprotected inter-
course or contraceptive failure. Before prescribing UPA
and all other ECPs pregnancy must be excluded, usually
by reviewing dates and the nature of the last period. Un-
like LNG, UPA is able to prevent follicular rupture and
to potentially prevent pregnancy even when given in ad-
vanced follicular stage of the menstrual cycle and thus
provides a longer treatment window than LNG. Because
of superior efficacy within 24 hours, 72 hours and 120
hours from unprotected intercourse when compared to
LNG, UPA is recognized as the most effective ECP, and
recently recommended as the first prescription choice for
all women regardless of the age and timing after inter-
course.
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ULIPRISTAT ACETAT U HITNOJ KONTRACEPCIJI
S A @ E T A K
Unato~ dostupnosti vrlo u~inkovitih metoda kontracepcije, u~estalost ne`eljenih trudno}a vrlo je visoka. Neplanira-
ne trudno}e dovode do niza zdravstvenih rizika, te nose socijalne i ekonomske posljedice. Hitna kontracepcija umanjuje
rizik od trudno}e nakon neza{ti}enog spolnog odnosa, i predstavlja mogu}nost za smanjenje broja neplaniranih trud-
no}a i poba~aja. Pilule za hitnu kontracepciju (eng. emergency contraceptive pill, ECP) sprije~avaju trudno}u odga-
|aju}i ili inhibiraju}i ovulaciju, bez interferencije sa postfertilizacijskim procesom. Ukoliko je do trudno}e ve} do{lo,
ECP ne}e biti u~inkovita. Stoga se ECP ne smatraju abortivnim sredstvima. Ulipristal acetat (UPA) (17a-acetoksi-
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-11b-(4N-N, N-dymethilaminophenyl)-19-norpregna-4,9-dien-3,20-dion) je prvi lijek koji je posebno razvijen i licenciran
za upotrebu kao hitni kontraceptiv. Ulipristal acetat je oralno aktivni, sinteti~ki, selektivni modulator progesteronskih
receptora koji djeluje ve`u}i se s visokim afinitetom za humani receptor za progesteron. Posjeduje i antagonisti~ke i
parcijalno agonisti~ke u~inke. Ulipristal acetat se smatra novim molekularnim entitetom i prvom komponentom far-
makolo{ke klase definirane kao pristalna osnova. S obzirom na dokazan klini~ki superioran u~inak, UPA je brzo pre-
poznat kao naju~inkovitije sredstvo za hitnu kontracepcijsu, te je nedavno preporu~en kao lijek prvog izbora za sve `ene
bez obzira na dob. Ovaj ~lanak daje pregled literature o UPA i njegovoj ulozi u hitnoj kontracepciji.
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